WO2002042769A1 - Procede de detection d'un anticorps anti-laminine-1 et sa mise en application - Google Patents
Procede de detection d'un anticorps anti-laminine-1 et sa mise en application Download PDFInfo
- Publication number
- WO2002042769A1 WO2002042769A1 PCT/JP2001/010138 JP0110138W WO0242769A1 WO 2002042769 A1 WO2002042769 A1 WO 2002042769A1 JP 0110138 W JP0110138 W JP 0110138W WO 0242769 A1 WO0242769 A1 WO 0242769A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- laminin
- antibody
- fragment
- sample
- patients
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/906—Fertility tests
Definitions
- the present invention relates to a method for measuring an autoantibody against laminin-1 (anti-laminin-1 antibody), a kit for performing the method, and a method for gynecological-related diseases such as habitual miscarriage, infertility, infertility, and endometriosis. It is related to clinical applications such as diagnosis. Background art
- Habitual miscarriage means repeated pregnancy but repeated spontaneous or stillbirth.
- the causes of this habitual miscarriage are diverse, including abnormalities in immune function.
- an anti-cardiolipin antibody As a means of diagnosing habitual miscarriage due to autoimmune causes, an anti-cardiolipin antibody (recently, the antigen of this autoantibody is a complex of cardiolipin and / 3-2-glycoside tin I (2-GPI))
- the method is known to measure J3 2-GPI-dependent anti-cardiolipin antibody).
- the reliability of the above method was not perfect, the possibility of habitual miscarriage could not be ruled out even if the measurement result was negative.
- satisfactory results have not been obtained even when other markers are combined and measured. Therefore, the development of a new marker different from the existing markers has been desired.
- Infertility, infertility and endometriosis are also similar to habitual miscarriage, and the development of a simpler and more reliable marker has been desired.
- Laminin is the most abundant glycoprotein found in basement membranes and forms a complex with other components of basement membranes such as nitrogen and type IV collagen.
- Laminin usually has an asymmetrical cross-shaped structure in which three polypeptides are combined in a coil shape, and the existence of many isoforms has been confirmed. That is, the combination of the three polypeptides that constitute laminin, ⁇ chain (up to 400 kDa), chain (up to 200 kDa), and ⁇ chain (up to 200 kDa)
- Various eyes Soforms can be formed, and to date, at least 12 isoforms have been reported to exist (J. Cell Biol., 137, 685-701 (1997), J. Cell Biol., 145, 605-618 (1999)).
- k-laminin laminin-6; ⁇ 3, ⁇ 1, y1)
- ks-laminin laminin-7; ⁇ 3, ⁇ 2, ⁇ 1)
- laminin or its fragments By detecting such laminin or its fragments, it can be used to diagnose various diseases such as liver fibrosis, cirrhosis, alcoholic liver fibrosis, diabetic complications, renal disease, chronic polyarthritis, tumors, and Alzheimer's disease. It is reported that there is a possibility.
- anti-laminin antibodies which are autoantibodies to laminin, are detected in the serum of aborted monkeys and monkeys, and when added to rat embryos cultured with serum containing anti-laminin antibodies, fetal It has been reported that abnormalities occur in mice and that abortion can be induced by immunizing mice with an anti-laminin antibody (Fertil. Steri., 51, 711-718 (1989), Teratology, 40, 47-57 (1989). ), Pro Natl. Acad. Sci. USA, 92, 6818-6822 (1995), Am. J. Pathol., 110, 346-357 (1983)) that anti-laminin antibodies cause abortion. It is speculated that this is one of them.
- the present inventors have focused on laminin as a new marker in gynecological-related diseases, and as a result of diligent studies, have found that laminin-1 (molecular weight: about 900 kDa) in various laminin isoforms
- laminin-1 molecular weight: about 900 kDa
- Anti-laminin-1 antibody which is an autoantibody, is present specifically in the serum of patients with gynecological-related diseases such as miscarriage, infertility, infertility, and endometriosis.
- the present inventors have found that the present invention is useful for diagnosing a disease and completed the present invention.
- the present invention comprises, after reacting a sample with laminin-1 or a fragment thereof, determining whether the anti-laminin-11 antibody in the sample has bound to laminin-1 or a fragment thereof.
- the present invention relates to a method for measuring anti-laminin-1 antibody.
- the present invention also relates to a kit containing laminin-11 or a fragment thereof as a constituent reagent and used in a method for measuring the amount of anti-laminin-1 antibody in a sample.
- the present invention relates to a method for detecting a gynecological-related disease from a measured value of an anti-laminin-1 antibody in sampnole measured by the above method or kit.
- 1A and 1B show the results of measurement of anti-laminin-1 antibody (IgGZlgM) in samples collected from healthy subjects, healthy pregnant women, and habitual abortions.
- IgGZlgM anti-laminin-1 antibody
- Figure 2 shows the results of measurement of anti-laminin-11 antibody (IgG) in sampnoles collected from healthy individuals who are not pregnant, infertile patients with endometriosis, and infertile patients without endometriosis. It is shown.
- IgG anti-laminin-11 antibody
- Figure 3 shows the relationship between the severity of endometriosis patients and anti-laminin-1 antibody levels.
- FIG. 4 shows the correlation between anti-laminin-11 antibody levels and CA-125 values.
- FIG. 5 shows the cross-reactivity of the anti-laminin-1 antibody with laminin-1 and the G domain of laminin-1 a1 chain in IVF patients.
- the sample to be measured is not particularly limited as long as it is a sample suspected of containing an anti-laminin-1 antibody.
- Specific examples of such a sample include human blood, serum, and plasma, and a serum and plasma sample is particularly preferable.
- the measurement of anti-laminin-11 antibody in the sample can be performed by reacting the sample with laminin-11 and then measuring whether the anti-laminin-11 antibody in the sample has bound to laminin-1. .
- laminin-1 As laminin-1 to be used, one prepared from cancer cells according to a known method (J. Biol. Chem., 254, 9933-9937 (1979)) or a commercially available laminin-1 (manufactured by Asahi Techno Glass Co., Ltd.) is used. be able to.
- a recombinant fragment produced by a DNA recombination technique using a fragment obtained by the enzyme or chemical treatment of laminin-11 or a gene encoding the same is used. May be used.
- Such fragments include, for example, the G domain of laminin- ⁇ 1 chain (amino acid residue 211-310; J. Biol. Chem., 275 (38) 29458-29465 (2000)). Is mentioned.
- Laminin-1 or a fragment thereof can be used in the form of a solid phase or a labeled form.
- the material of the carrier that can be used for immobilizing laminin-1 or a fragment thereof is not particularly limited as long as it has a high binding property to laminin-1 or a fragment thereof.
- polyvinyl chloride, polystyrene, styrene- Synthetic organic polymer compounds such as divinylbenzene copolymer, styrene-maleic anhydride copolymer, nylon, polybutyl alcohol, polyacrylamide, polyacrylonitrile, and polypropylene; dextran derivatives (such as Sephadex); and agarose gel (Sepharose, biogel, etc.), cellulose (paper disc, filter paper, etc.)
- inorganic polymer compounds such as glass, silica gel, silicone, etc., even if they have introduced functional groups such as amino, aminoalkyl, carboxyl, acyl, and hydroxyl groups. I don't care.
- the shape of the carrier examples include a plate shape such as a microtiter plate and a disk, a particle shape such as a bead, a tube shape such as a test tube and a tube, a fibrous shape and a film shape, and the like. You can choose.
- the immobilization of laminin-11 or a fragment thereof on the solid support may be performed by a known method such as a physical adsorption method, an ionic bonding method, a covalent bonding method, and an entrapment method.
- the solid phase reagent thus obtained may be subjected to a blocking treatment using a conventional blocking agent such as BSA, sugar, skim milk or the like in order to suppress non-specific binding.
- a conventional blocking agent such as BSA, sugar, skim milk or the like
- radioactive isotopes 3 2 P,: i H , 1 4 C, 1 2 5 I , etc.
- enzymes 3- Galata tosidase, peroxidase, alkaline phosphatase, etc.
- coenzymes 3- Galata tosidase, peroxidase, alkaline phosphatase, etc.
- coenzymes 3- Galata tosidase, peroxidase, alkaline phosphatase, etc.
- coenzymes e.g., ATP, biotin, heme, etc.
- fluorescent dyes fluorescein derivatives, rhodamine derivatives, etc.
- metal particles gold, silver, Platinum, etc.
- Labeling of laminin-1 or a fragment thereof can be carried out by a known method suitable for the selected labeling agent (for example, “Seismic Chemistry Laboratory Lecture 5 Immunobiochemical Research Method”, Tokyo Chemical Dojin, Ltd. Issue) See pages 102-112).
- the measurement of the anti-laminin-1 antibody in a sample using such a solid-phased product and / or a labeled product may be performed according to a method generally used as a method for measuring an antibody such as an autoantibody in a sample.
- the specific procedure for measuring anti-laminin-1 antibody in a sample using immobilized laminin-1 or a fragment thereof is as follows.
- a specific procedure for measuring an anti-laminin-1 antibody in a sample using labeled laminin-1 or a fragment thereof is, for example, as follows.
- the kit for measuring anti-laminin-1 antibody only needs to contain laminin-1 or a fragment thereof as a constituent reagent of the kit, and the other constituent reagents depend on the assay method used in the kit. If necessary, attach necessary reagents.
- the following kit can be exemplified as a kit for measuring anti-laminin-11 antibody using immobilized laminin-11 or a fragment thereof.
- kits for measuring anti-laminin-11 antibody using labeled laminin-11 or a fragment thereof include the following.
- reagents sample diluting solution, washing solution, enzyme substrate solution, reaction stopping solution, standard antibody solution, etc.
- sample diluting solution washing solution, enzyme substrate solution, reaction stopping solution, standard antibody solution, etc.
- the anti-laminin 1 Measure the body and compare it with the measurement of a healthy person. If the result is higher than the level of a healthy person, the possibility of gynecological-related diseases such as habitual abortion, infertility, infertility, endometriosis, etc. It is preferable to carry out a precision inspection.
- Women with miscarriage (habitual miscarriage) 2 0 7 (average age: 31.0 ⁇ 3.8 years, average number of miscarriages: 2.7 ⁇ 1. 1), healthy pregnant women 100 (average) Age: 30.7 Saturday, 4.5 years old) and 40 healthy (non-pregnant) women (mean age: 29.6 ⁇ 5.1 years old).
- the sample of 30 people with allergic diseases was excluded from the measurement.
- the ELISA of a 32-GPI-dependent anti-cardiolipin antibody was obtained by the method of Matsuura et al. (J. Immunol. 148, 3885-3891 (1992)) with some modifications. That is, a microtiter plate (Immulon-l: Dynex Technologies Inc.) made of polystyrene is coated with force lipolipin (2.5 ⁇ g Z50 ⁇ l nodule), and after blocking with 1% BSA, the human is treated. -Add GPI (1.0 / ig / 501) and 100-fold diluted serum sample (50 ⁇ l) to each well, mix well, and incubate at room temperature for 30 minutes.
- GPI 1.0 / ig / 501
- 100-fold diluted serum sample 50 ⁇ l
- cerebral kephalin as a phospholipid to determine the time to partially activate thromboplastin (aPPT), non-pregnant control plasma (50% mu 1), a standard plasma (5 0 ⁇ 1) and diluted brain cephalin the (1 00 ⁇ 1) were mixed, 3 7 ° accurately incubated for 3 minutes at C, 2 5mM C a C l 2 and 1 00 mu 1) and measure the clotting time.
- LA is considered positive if the prolonged clotting time (mean + 3 SD, longer than 7.37 seconds) does not return when the standard and sample plasmas are mixed 1: 1.
- AN ⁇ was measured by indirect immunofluorescence using a HepG 2 cell slide, and anti-DNA antibody was obtained from a commercially available kit. This was performed using
- Laminin-1 was prepared according to a known method (J. Biol. Chem., 254, 9933-9937 (1979)).
- Coat laminin 1 (10 ⁇ g / m 1) on a microtiter plate (Iron ulon-lB: Dynex Technologies In) (501 ⁇ g / m 1), incubate overnight at 4 ° C, then 10% After blocking with fetal calf serum, add a 200-fold diluted serum sample (100 ⁇ l Nowell) and incubate at room temperature for 1 hour.
- IgGZlgM horseradish peroxidase
- the level of anti-laminin-1 antibody (IgG) in a sample collected from a woman who had aborted habits was determined to be the same as that of a healthy pregnant woman and a healthy non-pregnant person.
- Anti-laminin 1 antibody IgG
- 55 out of 1-7 samples of habitual abortion were positive (31.1%) and 122 samples were negative (68. 9%).
- Anti-laminin-11 antibody IgM was positive in 49 samples (27.7%) and negative in 128 samples (72.3%).
- the probability of normal birth in an anti-laminin_1 antibody (IgG) -positive habitual miscarriage is the anti-laminin-1 antibody (IgG) -negative habitual miscarriage. It was found to be significantly lower than the probability of normal birth in.
- infertile patients undergoing laparoscopy or laparotomy (mean age: 33.4 sat 4.7 years, age range: 26-45 years), infertile patients undergoing artificial insemination and embryo transfer (IVF) 50 (Average age: 34.1 ⁇ 4.4 years, age range: 23-45 years, average number of times of artificial insemination: 2.8 ⁇ 2.6 times) and healthy person who is not pregnant (female) Plasma was collected from 39 patients (mean age: 29.6 ⁇ 5.1 years, age range: 22 to 41 years) and used as a sample. For IVF patients, plasma samples were collected the day before oocyte removal from the vagina. Table 4 shows the clinical profiles (fertility causes) of these infertile patients.
- infertility patients also included those with child abnormalities or hormonal abnormalities whose cause is unknown.
- Eight of 50 IVF patients had endometriosis. Fifty-three laparoscopic or laparotomy infertile patients were separated by laparoscopic or laparoscopic examination into those with endometriosis and those without. The severity of endometriosis patients was classified by a modification of the American Feritility Society (AFS) classification method. Of the 34 patients with endometriosis, 7 had stage I (minimal symptoms), 6 had stage II (mild symptoms), 13 had stage III (medium symptoms), and 8 had stage I (middle symptoms). IV (severe).
- AFS American Feritility Society
- the anti-laminin-11 antibody in the plasma sample was measured by a method substantially similar to that described in (2)) of Example 1.
- An anti-laminin-1 antibody was considered positive if the measured value was greater than the mean + SD of anti-laminin-1 antibody in plasma of healthy non-pregnant subjects.
- CA-125 in the sample was measured using a commercially available Radioimmunoassay kit (CA-125 II IRMA kit; Centcore, Inc., Malvern, PA) (Cancer Research 1984; 44: 1048-53). . The results were obtained from a standard curve. The 2 O U / m1 value was set as the force cutoff value. CA-125 is also used as a marker for endometriosis.
- FIG. 2 shows the results of measurement of anti-laminin-1 antibody (IgG) in samples obtained from healthy subjects who are not pregnant, infertile patients with endometriosis, and infertile patients without endometriosis.
- IgG anti-laminin-1 antibody
- FIG. 3 shows the results.
- anti-laminin-1 antibody levels in patients with stage II or stage III endometriosis infertility were significantly higher than those in stage I or IV patients.
- the levels in stage I and IV patients were not significantly different from those in patients without endometriosis. 4 out of 6 patients with stage II infertility (67%) and stage III infertility Seven of the 13 subjects (54%) were positive for anti-laminin-1 antibody.
- Table 5 shows the relationship between endometriosis and anti-laminin-1 antibody and CA-125 in IVF patients.
- the frequency of anti-laminin-11 antibody positivity in patients with IVF was significantly higher in patients with endometriosis than in patients without endometriosis (childhood endometriosis).
- Six out of 42 patients (14%) were positive, whereas 6 out of 8 patients with endometriosis (75%) were positive (p 0.003).
- No significant relationship was found between patients with endometriosis and the presence of CA-125 (even though 11 (26%) of 42 non-endometriosis patients were CA-125 positive).
- Fig. 5 shows the obtained results.
- the anti-laminin-11 antibody in the sample from the IV F patient cross-reacted with the G domain.
- a correlation was found between the immunoreactivity of the anti-laminin-1 antibody and one molecule of intactlaminin and the immunoreactivity of the anti-laminin-1 antibody and the G domain.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002214333A AU2002214333A1 (en) | 2000-11-22 | 2001-11-20 | Method of assaying antilaminin-1 antibody and application thereof |
US10/432,395 US7029867B2 (en) | 2000-11-22 | 2001-11-20 | Method of assaying antilaminin-1 antibody and application thereof |
JP2002544658A JP3989837B2 (ja) | 2000-11-22 | 2001-11-20 | 抗ラミニン−1抗体の測定法およびその応用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000355148 | 2000-11-22 | ||
JP2000-355148 | 2000-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002042769A1 true WO2002042769A1 (fr) | 2002-05-30 |
Family
ID=18827618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010138 WO2002042769A1 (fr) | 2000-11-22 | 2001-11-20 | Procede de detection d'un anticorps anti-laminine-1 et sa mise en application |
Country Status (4)
Country | Link |
---|---|
US (1) | US7029867B2 (ja) |
JP (1) | JP3989837B2 (ja) |
AU (1) | AU2002214333A1 (ja) |
WO (1) | WO2002042769A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005080980A1 (fr) * | 2004-02-20 | 2005-09-01 | Beijing Xinjing Antai Medical And Technology Service Limited Corp. | Procede pour diagnostiquer un avortement spontane recurrent immunitaire et procede de traitement et de suivi |
WO2005079814A1 (fr) * | 2004-02-20 | 2005-09-01 | Beijing Xinjing Antai Medical And Technology Service Limited Corp. | Composition pharmaceutique utilisee pour le traitement de l'avortement spontane recurrent et procede associe |
CN102657877A (zh) * | 2004-02-20 | 2012-09-12 | 北京新景安太医疗技术服务有限公司 | 免疫性习惯性流产的检查及监测方法 |
CN102657876B (zh) * | 2004-02-20 | 2014-07-30 | 北京新景安太医疗技术服务有限公司 | 免疫性习惯性流产的药物治疗及检测方法 |
WO2018016607A1 (ja) * | 2016-07-20 | 2018-01-25 | 国立大学法人京都大学 | IgG4関連疾患の検査方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1616939A1 (en) * | 2003-03-24 | 2006-01-18 | National Institute for Environmental Studies | Cell culture medium and solidified preparation of cell adhesion protein or peptide |
CN102621307B (zh) * | 2012-03-12 | 2014-04-30 | 沈周俊 | 尿层粘连蛋白在制备诊断膀胱癌的医疗器械中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0257194A (ja) * | 1979-06-11 | 1990-02-26 | Max Planck Ges Foerderung Wissenschaft Ev | 基底膜物質の免疫学的測定法のために好適なペプチドラミニンp1及びその製法 |
JPH04134097A (ja) * | 1990-09-21 | 1992-05-07 | Takara Shuzo Co Ltd | ラミニン フラグメント |
JPH0835966A (ja) * | 1994-03-01 | 1996-02-06 | Hadasit Medical Res Service & Dev Co Ltd | イムノアッセイ試薬、キットおよび方法 |
-
2001
- 2001-11-20 US US10/432,395 patent/US7029867B2/en not_active Expired - Fee Related
- 2001-11-20 WO PCT/JP2001/010138 patent/WO2002042769A1/ja active Application Filing
- 2001-11-20 JP JP2002544658A patent/JP3989837B2/ja not_active Expired - Fee Related
- 2001-11-20 AU AU2002214333A patent/AU2002214333A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0257194A (ja) * | 1979-06-11 | 1990-02-26 | Max Planck Ges Foerderung Wissenschaft Ev | 基底膜物質の免疫学的測定法のために好適なペプチドラミニンp1及びその製法 |
JPH04134097A (ja) * | 1990-09-21 | 1992-05-07 | Takara Shuzo Co Ltd | ラミニン フラグメント |
JPH0835966A (ja) * | 1994-03-01 | 1996-02-06 | Hadasit Medical Res Service & Dev Co Ltd | イムノアッセイ試薬、キットおよび方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005080980A1 (fr) * | 2004-02-20 | 2005-09-01 | Beijing Xinjing Antai Medical And Technology Service Limited Corp. | Procede pour diagnostiquer un avortement spontane recurrent immunitaire et procede de traitement et de suivi |
WO2005079814A1 (fr) * | 2004-02-20 | 2005-09-01 | Beijing Xinjing Antai Medical And Technology Service Limited Corp. | Composition pharmaceutique utilisee pour le traitement de l'avortement spontane recurrent et procede associe |
US7674590B2 (en) | 2004-02-20 | 2010-03-09 | Beijing Xinjing Antai Medical And Technology Service Limited Corp. | Methods for diagnosing and for monitoring the treatment of recurrent spontaneous abortion |
US7902162B2 (en) | 2004-02-20 | 2011-03-08 | Beijin Xinjing Antai Medical and Technology Service Limited Corp | Medicament and method for treating recurrent spontaneous abortion |
CN102657877A (zh) * | 2004-02-20 | 2012-09-12 | 北京新景安太医疗技术服务有限公司 | 免疫性习惯性流产的检查及监测方法 |
CN102657876B (zh) * | 2004-02-20 | 2014-07-30 | 北京新景安太医疗技术服务有限公司 | 免疫性习惯性流产的药物治疗及检测方法 |
CN102657877B (zh) * | 2004-02-20 | 2014-07-30 | 北京新景安太医疗技术服务有限公司 | 免疫性习惯性流产的检查及监测方法 |
WO2018016607A1 (ja) * | 2016-07-20 | 2018-01-25 | 国立大学法人京都大学 | IgG4関連疾患の検査方法 |
JPWO2018016607A1 (ja) * | 2016-07-20 | 2019-05-23 | 国立大学法人京都大学 | IgG4関連疾患の検査方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2002214333A1 (en) | 2002-06-03 |
US7029867B2 (en) | 2006-04-18 |
US20040082011A1 (en) | 2004-04-29 |
JP3989837B2 (ja) | 2007-10-10 |
JPWO2002042769A1 (ja) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Buyon et al. | Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. comparison of enzyme‐linked immunosorbent assay and immunoblot for measurement of anti–ss‐a/ro and anti–ss‐b/la antibodies | |
Stuart et al. | Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic diseases as measured by 125I‐radioimmunoassay | |
US5187065A (en) | Method and materials for detecting lyme disease | |
US10852302B2 (en) | Method for evaluation of function of phagocyte | |
CA2098180A1 (en) | Reagents and kits for determination of fetal restricted antigens | |
JP6707181B2 (ja) | 早産のリスクがある妊娠女性を同定するためのキットまたはパッケージ、および、当該キットまたはパッケージの使用 | |
US20030064424A1 (en) | Method of diagnosing transmissible spongiform encephalopathies | |
JPH02503714A (ja) | IgA腎臓病の診断のための方法及びキツト | |
WO2002042769A1 (fr) | Procede de detection d'un anticorps anti-laminine-1 et sa mise en application | |
US8030007B2 (en) | Method for the detection of endometriosis using an ME-2 antigen | |
JP5461581B2 (ja) | 自己免疫疾患を診断するための合成ペプチド、方法およびキット | |
JPH08506658A (ja) | 切迫分娩についての危険にある女性における膜の破裂を決定するための検定方法 | |
CN112816711B (zh) | 用于神经管畸形、先天性心脏病和唇腭裂胎儿产前无创诊断的分子标志物及其应用 | |
EP3477303A1 (en) | Method and means for diagnosing autoimmune hepatitis using autoantibody markers | |
JP2019168403A (ja) | 高安動脈炎の診断方法、診断マーカー及び診断キット | |
WO2003042701A2 (en) | Method for diagnosing multiple sclerosis and an assay therefore | |
Mogi et al. | Increased β2-microglobulin in both parotid and submandibular/sublingual saliva from patients with Sjögren's syndrome | |
JP2000193662A (ja) | 尿中シスタチンc測定試薬及び診断方法並びにキット | |
JP2915530B2 (ja) | ラミニン フラグメント | |
JP2949619B2 (ja) | 全身性エリテマトーデス病態診断剤 | |
KR20240100118A (ko) | 강직성 척추염 진단용 조성물, 키트 및 이의 정보제공방법 | |
CN116970693A (zh) | 作为早老性痴呆诊断标志物的ddit4l剪切产物 | |
JPH06324046A (ja) | 悪性腫瘍の検出方法及びキット | |
Begley et al. | Inhibition of pyruvate dehydrogenase activity: a new diagnostic test for primary biliary cirrhosis? | |
WO2018132639A1 (en) | Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002544658 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10432395 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |